

## **ELIXIR PHARMACEUTICALS TO PRESENT AT BIO CEO & INVESTOR CONFERENCE**

Feb 7 2008, 12:00 PM EST

Elixir Pharmaceuticals, Inc., announced today its President and Chief Executive Officer William K. Heiden is scheduled to present at the 10th Annual BIO CEO and Investor Conference in New York on Wednesday, February 13, 2008, at 2:00 p.m. ET in the Park Avenue Suite. The conference takes place at the Waldorf-Astoria Hotel in New York City.

Interested parties may access additional information about Elixir Pharmaceuticals at the Company's website, <http://www.elixirpharm.com>.

### About Elixir Pharmaceuticals

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease. Elixir's product pipeline includes a number of products which the Company believes will have significant advantages over existing products and will address unmet medical needs of the large metabolic disease markets. These include Elixir's phase III products, Glinsuna (mitiglinide) and Metgluna (mitiglinide plus metformin) for the treatment of Type 2 diabetes, and an oral ghrelin antagonist, a compound which blocks the receptor for the hormone, ghrelin which represents a potential next-generation treatment for a number of metabolic diseases. In addition, Elixir has built upon its knowledge of ghrelin, to advance an oral ghrelin agonist, a compound which stimulates the receptor for ghrelin. The Company's sirtuin products are exemplary of how Elixir continues to use its understanding of the pathways which slow the aging process to identify interesting targets for the development of drugs to treat metabolic disease.

CONTACT: Elixir Pharmaceuticals

William Heiden, 617-995-7000

or

Burns McClellan for Elixir Pharmaceuticals

Media:

Justin Jackson, 212-213-0006

[jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)

or

Investors:

Juliane Snowden, 212-213-0006

[jsnowden@burnsmc.com](mailto:jsnowden@burnsmc.com)

or

Nicki Kahner, 212-213-0006

[nkahner@burnsmc.com](mailto:nkahner@burnsmc.com)